- Home
- SAR vs TERN Comparison
SAR vs TERN Comparison
Compare SAR & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAR
- TERN
- Stock Information
- Founded
- SAR 2007
- TERN 2017
- Country
- SAR United States
- TERN United States
- Employees
- SAR N/A
- TERN N/A
- Industry
- SAR Investment Managers
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- SAR Finance
- TERN Health Care
- Exchange
- SAR Nasdaq
- TERN Nasdaq
- Market Cap
- SAR 337.6M
- TERN 310.8M
- IPO Year
- SAR 2007
- TERN 2021
- Fundamental
- Price
- SAR $23.43
- TERN $3.04
- Analyst Decision
- SAR Buy
- TERN Buy
- Analyst Count
- SAR 4
- TERN 5
- Target Price
- SAR $25.08
- TERN $18.38
- AVG Volume (30 Days)
- SAR 88.4K
- TERN 1.0M
- Earning Date
- SAR 05-07-2025
- TERN 05-08-2025
- Dividend Yield
- SAR 14.13%
- TERN N/A
- EPS Growth
- SAR 186.33
- TERN N/A
- EPS
- SAR 2.02
- TERN N/A
- Revenue
- SAR $148,855,238.00
- TERN N/A
- Revenue This Year
- SAR $6.07
- TERN N/A
- Revenue Next Year
- SAR N/A
- TERN N/A
- P/E Ratio
- SAR $11.64
- TERN N/A
- Revenue Growth
- SAR 3.57
- TERN N/A
- 52 Week Low
- SAR $21.10
- TERN $1.87
- 52 Week High
- SAR $26.49
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- SAR 44.44
- TERN 51.89
- Support Level
- SAR $22.22
- TERN $2.93
- Resistance Level
- SAR $25.11
- TERN $3.62
- Average True Range (ATR)
- SAR 0.56
- TERN 0.25
- MACD
- SAR -0.05
- TERN 0.03
- Stochastic Oscillator
- SAR 37.54
- TERN 39.27
About SAR Saratoga Investment Corp New
Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests primarily in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.